PT - JOURNAL ARTICLE AU - C Casado AU - A Gil AU - ME Martínez AU - JM Ramón AU - L López AU - T Molina TI - CPC-058 Factors Associated with Antiretroviral Medicines Adherence Among HIV-Infected Children AID - 10.1136/ejhpharm-2013-000276.515 DP - 2013 Mar 01 TA - European Journal of Hospital Pharmacy: Science and Practice PG - A186--A186 VI - 20 IP - Suppl 1 4099 - http://ejhp.bmj.com/content/20/Suppl_1/A186.1.short 4100 - http://ejhp.bmj.com/content/20/Suppl_1/A186.1.full SO - Eur J Hosp Pharm2013 Mar 01; 20 AB - Background The aims of highly active antiretroviral therapy (HAART) in HIV-infected children are to achieve and sustain full HIV-RNA viral load (VL) suppression and CD4-reconstitution, in order to prevent the progression of the HIV infection and allow normal growth and development. Adherence to HAART is a strong predictor of therapeutic efficacy. Previous studies have shown that therapeutic success requires adherence > 95%. Among paediatric HIV patients, adherence to HAART is reportedly suboptimal. There are a number of factors that can compromise treatment compliance. These can be classified as those related to the medicine, the patient, the family/caregiver and the healthcare system. Purpose To estimate the correlation between adherence to HAART and treatment efficacy. To assess factors related to non-adherence among HIV-infected children. Materials and Methods Retrospective cohort study from January 2008 to July 2012 including all HIV-infected patients on HAART followed by the Paediatrics Department. Age, sex, lipoatrophy, number of pills/day (P/d) and frequency of daily dosing: once a day (QD) or twice a day (BID), were analysed. Adherence was assessed by using the pharmacy refill records and pill count, according to the following formula: Adherence (%) = (Nº dispensed doses- Nº returned doses)/Nº prescribed doses × 100 Undetectable VL was defined as VL < 20 copies/ml. Data were analysed by multiple logistic regression methods using SPSS software (version 19.0). Results 24 HIV-infected patients were included (mean age = 15.3 ± 5.5 years; 29.2% male, 70.8% female). 37.5% of patients presented lipoatrophy. 54.2% and 45.8% of the children were treated with a QD and BID regimen, respectively. Only 50% of patients were considered adherent to treatment (adherence >95%). The relationship between risk factors and adherence was: see Table Patients with poor adherence had a higher risk of virological failure (OR = 11.67; CI95 = 1.14–119.54;p = 0.039) Conclusions Adherence to HAART represents a significant challenge in the paediatric HIV population. The P/d was significantly associated with adherence. Every pill/day increased up to 2.3-fold the risk of non-adherence to HAART. Simplifying HAART by reducing the pill burden may contribute to improving compliance in the paediatric HIV population. View this table:Abstract CPC-058 Table 1 No conflict of interest.